Translocator protein (TSPO) as a molecular imaging biomarker of pancreatic cancer

摘要: 7 Objectives Although great advances have been made in imaging techniques, surgery, and treatment for pancreatic cancer, outcomes failed to improve over the past 25 years. A key improving cancer is development of capabilities that allow early detection lesions at a time when disease curable stage. The only positron emission tomography (PET) tracer routinely used this setting, 18F-FDG, has low sensitivity specificity cancer. We identified TSPO as potential biomarker neoplasias. Elevated expression well documented many forms (e.g. colon, breast, glioma), where levels correlate with tumor proliferation, invasion, metastasis. Methods Tissue microarrays (TMAs) human obtained from patients Vanderbilt were stained scored levels. novel ligand 18F-VUIIS-1018 was detect PANC1 orthotopic model genetically engineered mouse Ptf1acre/+;LSL-KrasG12D;Tgfbr2fl/fl. evaluated both models immunohistochemistry (IHC). Results significantly elevated all stages precursor compared normal pancreas chronic pancreatitis TMAs. observed robust uptake tumors arising Ptf1acre/+;LSL-KrasG12D;Tgfbr2fl/fl mice. three-fold higher tissues adjacent non-tumor tissue. IHC validated increased Conclusions These studies lay foundation determining feasibility PET lesions. Further work will determine suitability advancing TSPO-PET Additionally, further include monitor progression predict response setting.